Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 6241 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 
Table of Contents
LETTER TO THE EDITOR
Year : 2011  |  Volume : 15  |  Issue : 8  |  Page : 409

Inappropriate concomitant use of amlodipine and simvastatin: A report on its incidence in a primary care unit


Wiwanitkit House, Bangkhae, Bangkok, Thailand

Date of Web Publication1-Nov-2011

Correspondence Address:
Somsri Wiwanitkit
Wiwanitkit House, Bangkhae, Bangkok 10160
Thailand
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2230-8210.86989

Rights and Permissions

How to cite this article:
Wiwanitkit S, Wiwanitkit V. Inappropriate concomitant use of amlodipine and simvastatin: A report on its incidence in a primary care unit. Indian J Endocr Metab 2011;15, Suppl S4:409

How to cite this URL:
Wiwanitkit S, Wiwanitkit V. Inappropriate concomitant use of amlodipine and simvastatin: A report on its incidence in a primary care unit. Indian J Endocr Metab [serial online] 2011 [cited 2020 Feb 29];15, Suppl S4:409. Available from: http://www.ijem.in/text.asp?2011/15/8/409/86989

Sir,

Metabolic syndrome (diabetes mellitus, dyslipidemia, hypertension and obesity) is a common metabolic disorder that can be seen around the world. Polypharmacy can be expected in patients with this syndrome and it sometimes causes adverse effects due to drug interaction. An important concern is the inappropriate concomitant use of amlodipine and simvastatin. It is reported that concomitant use can result in double dosing of simvastatin due to common passing of the CYP3A4, [1] and this can be a risk factor for myopathy.

Here, the authors report on incidence of inappropriate concomitant use of amlodipine and simvastatin in a primary care unit of a tertiary hospital (the name is blinded due to privacy). Based on the data of 600 dyslipidemic cases in this setting, 120 (20%) cases were administered high-dose simvastatin (40 mg/day). Of interest, 30 (5%) had inappropriate concomitant use of amlodipine and simvastatin.

This implies that general practitioners might not know the fact that concomitant use of amlodipine and high dosage of simvastatin can be a risk factor for myopathy.

 
   References Top

1.Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, Ohashi K. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res 2005;28:223-7.  Back to cited text no. 1
[PUBMED]  [FULLTEXT]  



This article has been cited by
1 Evaluation of Antioxidant, Anti-Inflammatory, Antithrombotic, and Antiobesity Activities in Cultured Edible Plants to Increase Farm Income
Seon-Hye Lee,Nam-Seok Kim,Bong-Kyoum Choi,Yeon-Hee Park,Jung-Bong Kim,Hwan-Hee Jang,Yu-Jin Hwang,Jeong-Sook Choe,Sung-Hyen Lee
The Korean Journal of Community Living Science. 2017; 28(1): 29
[Pubmed] | [DOI]
2 Oral mucositis, Steven Johnson syndrome and amlodipine usage in a case with metabolic syndrome
Somsri Wiwanitkit,Viroj Wiwanitkit
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2012; 6(2): 112
[Pubmed] | [DOI]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed1439    
    Printed47    
    Emailed0    
    PDF Downloaded412    
    Comments [Add]    
    Cited by others 2    

Recommend this journal